openPR Logo
Press release

Undervalued Stocks: SNYR, VNCE, OPEN, AMST - Under $10 in Focus

09-11-2025 07:46 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Undervalued Stocks: SNYR, VNCE, OPEN, AMST - Under $10 in Focus

Several small-cap and micro-cap stocks trading under $10 are attracting fresh investor attention this week. While each presents unique opportunities, they also come with significant risks. Here's a look at six names in the spotlight.

Synergy CHC Corp. (NASDAQ: SNYR) a consumer health and wellness company best known for its flagship FOCUSfactor Registered brand, is trading near $2.19 per share. The company recently completed a $4.3 million stock offering, positioning it to accelerate global expansion and drive revenue growth over the next 12-18 months. Synergy remains fundamentally strong, reporting 10 consecutive profitable quarters as of Q2 2025, see more here [https://s3.amazonaws.com/sec.irpass.cc/2988/0001213900-25-076060.htm]. The stock carries a low price-to-earnings ratio and favorable sales multiples, supporting its case as undervalued on paper. While past year-over-year revenue declines and dilution risks have raised investor concerns, analysts maintain price targets as high as $10, see Roth Capital report, (read more here) [https://thestreetreports.com/wp-content/uploads/2025/06/SNYR-Roth-updated-report.pdf] underscoring the potential upside if execution holds.

Synergy's FOCUSfactor Registered brand has a 25-year legacy and wide distribution through major retailers including Costco (NASDAQ: COST), Walmart (NYSE: WMT), Amazon (NASDAQ: AMZN), CVS (NYSE: CVS), and Walgreens (NASDAQ: WBA), with reach across the U.S., Canada, and the U.K. Synergy also benefits from a $12.4 million surplus, active licensing agreements in the UAE and Turkey, and recent retail expansion into 1,600+ EG America stores. Through its McKesson partnership, the company has distribution access to more than 50,000 outlets. With this infrastructure in place, Synergy is strategically positioned to accelerate growth and expand globally into 2026.

Vince Holding Corp. (NYSE: VNCE) Luxury apparel retailer Vince Holding Corp. is trading around $3.20. Recent quarterly results showed net sales slipping slightly, but gross margins improved to just over 50%. The direct-to-consumer segment grew, offsetting wholesale weakness. While Vince faces NYSE listing compliance pressures, its margin improvements and brand recognition provide a potential foundation for recovery. Investors see this as a turnaround story, though risks remain high.

Opendoor Technologies (NASDAQ: OPEN) surged on news of a leadership shake-up. Former Shopify COO Kaz Nejatian has been appointed CEO, with co-founders Keith Rabois and Eric Wu returning to leadership roles and investing $40 million into the business. The stock rallied sharply on renewed optimism, though analysts caution that profitability challenges persist. The company's turnaround story remains speculative but has captured investor enthusiasm.

Amesite Inc. (NASDAQ: AMST) AI-powered digital learning company following strong growth in its enterprise business. Recent highlights include a 63% revenue increase from its NurseMagic Trademark Enterprise product and the launch of new AI-driven form automation tools. Despite early-stage momentum, the company continues to face challenges with cash burn and profitability. For speculative investors, Amesite offers exposure to a high-growth niche in enterprise SaaS and education technology.

The under-$10 stock arena remains a dynamic space where opportunity and volatility go hand in hand. Companies like Synergy CHC Corp. "FocusFactor" (NASDAQ: SNYR) and Vince Holding (NYSE: VNCE) are working to stabilize and grow through strategic initiatives, while Opendoor (NASDAQ: OPEN) and Amesite (NASDAQ: AMST) are leaning on leadership changes and innovation to fuel momentum. Each presents a unique narrative, but all require careful monitoring as execution risks remain high.

For investors, the key takeaway is that undervalued small-caps can deliver outsized returns, but they also demand patience, risk tolerance, and an eye for fundamental shifts. As these companies navigate expansion, restructuring, and new product launches, their progress over the next 12 to 18 months will determine whether today's discounts turn into tomorrow's opportunities.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=undervalued-stocks-snyr-vnce-open-amst-under-10-in-focus]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Undervalued Stocks: SNYR, VNCE, OPEN, AMST - Under $10 in Focus here

News-ID: 4179841 • Views:

More Releases from ABNewswire

How to Pick the Best Online Chemistry Tutoring Platform
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject. Essential Platform Features for Effective Online Chemistry Tutoring Modern chemistry tutoring
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our

All 5 Releases


More Releases for NASDAQ:

Peraso (NASDAQ: PRSO) Pushes Back on Mobix Labs (NASDAQ: MOBX) Takeover Bid, Val …
Peraso Inc. (NASDAQ: PRSO), a leading innovator in mmWave wireless solutions, has officially acknowledged receipt of an unsolicited, non-binding acquisition proposal from Mobix Labs, Inc. (NASDAQ: MOBX). The offer proposes a stock-for-stock exchange that values Peraso at approximately $1.20 per share, representing a 20% premium over its 30-day average closing price. However, Peraso is contesting several key points made in Mobix's June 26 press release. Financials Mischaracterized, Says Peraso Peraso rebuffed Mobix's
ZenaTech's (Nasdaq: ZENA) Nasdaq Listing: A Launchpad for Growth and Innovation
On October 1, ZenaTech (Nasdaq: ZENA) made its debut on the Nasdaq, a pivotal milestone for the company specializing in AI-driven drone solutions and enterprise SaaS (software-as-a-service) applications. As businesses increasingly seek innovative ways to streamline operations and boost productivity, ZenaTech stands ready to meet these demands with its advanced AI drone solutions and comprehensive software applications. Under the leadership of CEO Dr. Shaun Passley, ZenaTech aims to leverage its
Investors Alert: EMCORE (NASDAQ: EMKR), AGBA Group (NASDAQ: AGBA), Peraso Inc. ( …
EMCORE Corporation (NASDAQ: EMKR) saw its shares soar today following a major announcement from Mobix Labs (NASDAQ: MOBX). Mobix Labs, a leader in advanced wireless solutions for military and defense, has submitted a proposal to acquire all outstanding shares of EMCORE for $3.80 per share in cash, positioning itself as a key player in the aerospace and defense sectors. This move could provide immediate value to shareholders, making it an
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO) …
Pre-market trading is heating up as Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) surges on positive Phase 2 data for its cancer treatment BDTX-1535. Peraso Inc. (NASDAQ: PRSO) continues its expansion into the Asian markets and a major military contract. Kaival Brands (NASDAQ: KAVL) saw its stock surge in early trading today on merger announcement. Other stocks to watch include Banzai International Inc. (NASDAQ: BNZI), which saw a 97.51% rally after
Lawsuit filed for Investors who lost money with Alphabet Inc. (NASDAQ: GOOG, NAS …
An investor, who purchased shares of Alphabet Inc. (NASDAQ: GOOG, NASDAQ: GOOGL), filed a lawsuit over alleged violations of Federal Securities Laws by Alphabet Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Alphabet Inc. (NASDAQ: GOOG, NASDAQ: GOOGL), have certain options and for certain investors are short and strict deadlines running. Deadline: May 15, 2023. NASDAQ: GOOG, NASDAQ: GOOGL investors should contact the Shareholders
Investigation announced for Investors in NASDAQ: MTTR over possible Wrongdoing a …
An investigation was announced for investors in shares of Matterport, Inc. (NASDAQ: MTTR) was announced over potential breaches of fiduciary duties by certain officers and directors at Matterport, Inc. Investors who purchased shares of Matterport, Inc. (NASDAQ: MTTR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Matterport, Inc. directors breached their fiduciary duties and